Mature Cystic Teratoma of Ovary with Abnormally High Levels of Ca19-9: A Case Report

Sampaio, Joana; Sarmento-Gonçalves, Inês; Barros, Joana Moreira; Félix, Joana; Tiago-Silva, Pedro

doi:10.1055/s-0036-1586161

Cited by 4 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pyeon et al [5] reported a case of a benign ovarian cyst with CA 19-9 levels of 2,753 U/mL that then returned to normal postoperatively [5]. Similarly, Sampaio et al [4] reported an MCT in a 50-year-old woman with the second highest reported level of CA 19-9 (8922.75 U/mL) [4]. These findings have led to more comprehensive research.…”

Section: Discussionmentioning

confidence: 98%

“…We present this case in order to build on the growing body of evidence suggesting that CA 19-9 levels are useful in the diagnosis and management of MCT [7,10]. Cases of ovarian neoplasms such as ovarian clear-cell and endometrioid carcinomas [11] with increased CA 19-9 levels, and benign neoplasms with increased CA 19-9 have been documented in the literature previously [3][4][5]. Pyeon et al [5] reported a case of a benign ovarian cyst with CA 19-9 levels of 2,753 U/mL that then returned to normal postoperatively [5].…”

Section: Discussionmentioning

confidence: 99%

“…In general, the accepted normal reference range of CA 19-9 is <37 U/mL. Aside from a handful of case reports [1][2][3][4][5] and larger analyses [5][6][7] the association between elevated CA 19-9 level and Mature Cystic Teratoma (MCT) is scarcely reported. Yet, CA 19-9's role in diagnosis remains unclear.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

CA 19-9 Elevation in a Benign Ovarian Cystic Teratoma, A Case Report and Review of Literature

Rezai¹,

Lieberman²,

Raza³

et al. 2017

OGIJ

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

CA 19-9 Elevation in a Benign Ovarian Cystic Teratoma, A Case Report and Review of Literature

Rezai¹,

Lieberman²,

Raza³

et al. 2017

OGIJ

View full text Add to dashboard Cite

“…Herein, we report six cases of patients with AIP, causing the elevation of CA 19-9 ranging from 1950 U/mL to 12,000 U/mL, and a case of a patient with liver steatosis and an increased CA 19-9 value to 1930 U/mL. When considering differential diagnosis due to the low specificity of tumor markers and lack of obvious radiological image, various diseases should be taken into consideration [ 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 68 , 69 ]; however, a mildly increased dimension of the pancreas in MRI with areas of fluid signals could correspond to past AIP that induced increased CA 19-9. According to the literature, about 25% of patients with AIP show values of CA 19-9 > 37 U/mL, and only around 12.2% of them show elevated levels > 100 U/mL [ 70 ].…”

Section: Discussionmentioning

confidence: 99%

Significantly Elevated CA 19-9 after COVID-19 Vaccination and Literature Review of Non-Cancerous Cases with CA 19-9 > 1000 U/mL

Ciesielka,

Jakimów,

Tekiela

et al. 2024

JCM

View full text Add to dashboard Cite

Background: CA 19-9 is a commonly assessed tumor marker, considered characteristic of pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancers; however, the positive predictive value of CA 19.9 is too low, and the usage of CA 19.9 as a screening tool in the healthy population remains controversial. Methods: The presented case illustrates a reversed diagnosis of highly elevated serum CA 19-9 levels in a 54-year-old female complaining of pain in the epigastric region, shortly after COVID-19 vaccination. Laboratory tests showed a significantly elevated level of the CA 19-9 marker (>12,000 U/mL, reference value: <37 U/mL) with normal pancreatic enzyme activity. The patient underwent imaging examination, which showed no abnormalities, except for increased pancreatic dimension and areas of fluid signal in the pancreas in magnetic resonance imaging (MRI), which may correspond to autoimmune pancreatitis (AIP). The patient remains asymptomatic with a recommendation for a follow-up MRI in 12 months. Results: A literature review conducted revealed multi-causal CA 19-9 increases above 1000 U/mL, including non-cancerous diseases of the lung, pancreas, liver, ovary, kidney, and others. The median concentration of CA 19-9 regardless of the cause of disease was 2810 U/mL (IQR ± 6895). The median CA 19-9 values in men and women were 3500 (IQR ± 10,050) and 2455 (IQR ± 3927), respectively, and differ significantly between the compared groups (p < 0.05). There was no difference between CA 19-9 values and the categorized cause of the increase. Conclusions: Conducting differential diagnosis, it should not be forgotten that most international guidelines recommend the use of CA 19-9 only in conjunction with pathology of pancreas in radiological imaging; however, even such a combination can point the diagnostic pathway in the wrong direction. A highly elevated CA 19-9 level, typically associated with PDAC, may be the result of benign disease including AIP related to COVID-19 vaccination.

show abstract

“…As a tumor marker, CA 19-9 had a relationship with anxiety in our study. Also, a case report concluded that a high level of CA 19-9 is not necessarily associated with ovarian malignancy and may be due to patients' anxiety (34). Overall, tumor markers such as CA 125 and CA 19-9 can elevate in various non-malignant processes, including liver diseases.…”

Section: Discussionmentioning

confidence: 99%

Psychological, Cognitive, and Laboratory Characteristics of End-Stage Liver Disease Patients

et al. 2020

View full text Add to dashboard Cite

Background: End-Stage Liver Disease (ESLD) causes several clinical and psychological comorbidities. Some accompanying psychiatric disturbances have significant effects on the patients’ quality of life. Objectives: Thus, we aimed to evaluate some psychological characteristics of ESLD patients. Methods: A cross-sectional study was conducted on 91 ESLD patients aged 18 - 70 years. We assessed the patients using the California Verbal Learning Test (CVLT), Fatigue Severity Scale, Epworth Sleepiness Scale, and Hospital Anxiety and Depression Scale. Also, we measured the demographic and some laboratory data of the participants. The data were analyzed by SPSS version 21 software, and P values of less than 0.05 were considered significant. Results: The study included 68 men and 23 women with a mean age of 41.9 ± 13.72 years (range 19 - 68). The mean scores of fatigue (40.6 ± 14.8) and anxiety (12.98 ± 2.76) were more than the normal range. The most significant association was seen between age and CVLT items (attention (P = 0.01), immediate memory (P < 0.001), short delay free recall (0.01), and short delay cued recall (0.03). Conclusions: End-stage liver disease patients had anxiety, fatigue, and memory disorders in addition to their poor clinical conditions. Although the main treatment of ESLD is liver transplantation but the psychological and cognitive problems before transplantation in these patients are prognostic factors for post-operation compliance and follow up.

show abstract

Mature Cystic Teratoma of Ovary with Abnormally High Levels of Ca19-9: A Case Report

Cited by 4 publications

References 16 publications

CA 19-9 Elevation in a Benign Ovarian Cystic Teratoma, A Case Report and Review of Literature

CA 19-9 Elevation in a Benign Ovarian Cystic Teratoma, A Case Report and Review of Literature

Significantly Elevated CA 19-9 after COVID-19 Vaccination and Literature Review of Non-Cancerous Cases with CA 19-9 > 1000 U/mL

Psychological, Cognitive, and Laboratory Characteristics of End-Stage Liver Disease Patients

Contact Info

Product

Resources

About